HC Wainwright Issues Pessimistic Estimate for AKBA Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Stock analysts at HC Wainwright cut their FY2026 EPS estimates for Akebia Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn ($0.12) per share for the year, down from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2026 earnings at ($0.03) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.07) EPS, FY2029 earnings at $0.04 EPS and FY2030 earnings at $0.15 EPS.

Other equities research analysts have also recently issued research reports about the company. Leerink Partners cut Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price objective for the company. in a research note on Friday, August 7th. Zacks Research raised Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Akebia Therapeutics in a research report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Akebia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Akebia Therapeutics Stock Up 2.7%

AKBA stock opened at $0.87 on Monday. The stock’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $1.26. The company has a market cap of $240.12 million, a P/E ratio of -7.88 and a beta of 0.26. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.35 and a current ratio of 1.43. Akebia Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $3.40.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%.The company had revenue of $49.13 million during the quarter, compared to the consensus estimate of $48.85 million.

Institutional Trading of Akebia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Ieq Capital LLC bought a new position in shares of Akebia Therapeutics in the second quarter valued at approximately $105,000. Virtus Advisers LLC bought a new stake in Akebia Therapeutics during the second quarter worth $360,000. Empirical Asset Management LLC bought a new stake in Akebia Therapeutics during the second quarter worth $40,000. BlackRock Inc. purchased a new stake in Akebia Therapeutics in the 2nd quarter valued at $22,784,000. Finally, Deutsche Bank AG purchased a new stake in Akebia Therapeutics in the 2nd quarter valued at $293,000. 33.92% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Erik Ostrowski sold 56,019 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $1.11, for a total value of $62,181.09. Following the transaction, the chief financial officer owned 616,616 shares of the company’s stock, valued at approximately $684,443.76. This trade represents a 8.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.30% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.